Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
27.35
+0.02 (0.07%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $105.40M in the quarter ending March 31, 2026, with 60.07% growth. This brings the company's revenue in the last twelve months to $415.62M, up 95.29% year-over-year. In the year 2025, Arcutis Biotherapeutics had annual revenue of $376.07M with 91.34% growth.
Revenue (ttm)
$415.62M
Revenue Growth
+95.29%
P/S Ratio
8.23
Revenue / Employee
$1,174,079
Employees
354
Market Cap
3.42B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.07M | 179.53M | 91.34% |
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Arcus Biosciences | 236.00M |
| IDEAYA Biosciences | 225.27M |
| Tango Therapeutics | 56.99M |
| NewAmsterdam Pharma Company | 22.57M |
| Alumis | 8.40M |
ARQT News
- 10 days ago - Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board - TheFly
- 10 days ago - Arcutis Expands Board of Directors with Appointment of Chris Peetz - GlobeNewsWire
- 10 days ago - Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 - GlobeNewsWire
- 18 days ago - Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA - TheFly
- 18 days ago - FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - GlobeNewsWire
- 23 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - GlobeNewsWire
- 26 days ago - FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream - TheFly